Ozempic Gastroparesis Attorney: Lawsuit Eligibility Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Specific Concerns

For decades, the public health landscape has been shaped by broad educational initiatives aimed at improving general wellness and disease prevention. These efforts have provided foundational knowledge about nutrition, exercise, and routine medical screenings, empowering individuals to make informed lifestyle choices. Within this framework, discussions of pharmaceutical interventions have typically focused on their intended benefits for chronic conditions such as diabetes and obesity, emphasizing adherence to prescribed regimens and regular monitoring. As the understanding of medication effects has evolved, attention has increasingly turned to the full spectrum of outcomes associated with long-term drug exposure. This shift in perspective moves beyond general health promotion to examine specific, unintended consequences that may arise during treatment. In particular, the widespread use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has prompted closer scrutiny of their potential impact on gastrointestinal function. This transition from a general health context to a more targeted concern reflects a natural progression in public health discourse. The focus now narrows to individuals who have used Ozempic and subsequently developed symptoms consistent with gastroparesis, a condition characterized by delayed gastric emptying. For those affected, understanding the legal landscape surrounding potential liability becomes a pertinent consideration, marking a clear pivot from general health information to a specific exposure-related inquiry.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known risks, gastrointestinal adverse reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: Symptoms, Diagnosis, and Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath testing. The condition can be idiopathic or secondary to diabetes, surgery, or medications. Ozempic, by slowing gastric emptying as part of its mechanism of action, may exacerbate or induce gastroparesis-like symptoms. While the drug label does not explicitly list gastroparesis as a separate adverse reaction, it reports gastrointestinal adverse reactions with a frequency of <5% associated with Ozempic: dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the drug’s known effect on gastric motility provides a mechanistic link.

Mechanistic Evidence and Risk Context

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological in susceptible individuals, leading to persistent gastroparesis. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, some patients may develop symptoms after prolonged use or after dose increases. The label does not provide specific data on the incidence of gastroparesis as a distinct diagnosis, but the high rate of gastrointestinal adverse reactions—up to 36.4% with 1 mg—suggests a significant risk.

Legal Considerations for Ozempic Users

Regarding the adequacy of warnings, the Ozempic label includes a section on gastrointestinal adverse reactions but does not explicitly warn about gastroparesis. The label states that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and advises discontinuation if such reactions occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, no specific warning about gastroparesis or delayed gastric emptying as a potential adverse effect is included. This omission may be relevant for patients who develop severe or persistent gastrointestinal symptoms, as they may not be adequately informed of the risk. The label does note that gastrointestinal adverse reactions led to discontinuation in 3.1% to 3.8% of patients, indicating that these symptoms can be severe enough to warrant stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients who have developed gastroparesis after using Ozempic, attorney-related considerations include evaluating whether the drug’s labeling provided sufficient warning. The absence of a specific gastroparesis warning may support claims of inadequate risk communication. Additionally, the timeline between exposure and symptom onset is critical; patients who experienced symptoms during dose escalation or shortly after starting treatment may have a stronger case for causation. The mechanistic pathway—delayed gastric emptying due to GLP-1 receptor agonism—is well-established, and the high frequency of gastrointestinal adverse reactions in clinical trials provides epidemiological support. However, individual cases require careful documentation of symptom onset, duration, and exclusion of other causes. In summary, Ozempic is associated with a high rate of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug’s label does not explicitly warn about gastroparesis, which may affect legal claims regarding inadequate warnings. Patients who have experienced persistent nausea, vomiting, or other gastroparetic symptoms after Ozempic use should consult a healthcare provider and consider legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Can Ozempic cause gastroparesis?

Ozempic, by slowing gastric emptying as part of its mechanism of action, may exacerbate or induce gastroparesis-like symptoms. While the drug label does not explicitly list gastroparesis as a separate adverse reaction, it reports gastrointestinal adverse reactions with a frequency of <5% that overlap with gastroparesis symptoms, and the high rate of gastrointestinal adverse reactions—up to 36.4% with 1 mg—suggests a significant risk.

What legal options are available for individuals who developed gastroparesis after using Ozempic?

Individuals who developed gastroparesis after using Ozempic may have legal claims based on inadequate warnings. The Ozempic label does not explicitly warn about gastroparesis, which may support claims of insufficient risk communication. Patients should consult a healthcare provider and consider legal evaluation to assess their case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.